Disclosure Under Chapter 2 Section 10
(Thomson Reuters ONE) -
ORION CORPORATION STOCK EXCHANGE RELEASE 26 SEPTEMBER 2011 at 1:25 PM EEST
Orion Corporation (business code 1999212-6) has received a disclosure under
Chapter 2, Section 9 of the Securities Markets Act, according to which the total
number of Orion B shares owned by the mutual funds under the management of
Capital Research and Management Company, has on 22 September 2011 through trades
in the course of ordinary business exceeded the one twentieth (1/20) threshold
of the total number of Orion Corporation shares.
The holding of the mutual funds under the management of Capital Research and
Management Company according to the disclosure:
Share type Number of shares Percent (%) of Percent (%)
total shares voting rights
A share 0 0 0
B share 7,196,174 5.0944 0.7135
ISIN:FI0009014377
Total 7,196,174 5.0944 0.7135
After the acquisition mentioned in the notification total 400,000 Orion
Corporation A-shares have been converted into 400,000 B-shares. After that the
total share of the voting rights of the mutual funds under the management of
Capital Research and Management Company is 0.7189. per cent.
The taxpayer I.D. advised by Capital Research and Management Company:
95-1411037. Additional information about the company: www.capgroup.com.
Orion Corporation's share capital comprises 141.257.828 shares, of which
45.247.646 are A shares and 96.010.182 are B shares. Each A share entitles its
holder to twenty (20) votes and each B share to one (1) vote. Thus, the total
number of votes is 1.000.963.102.
Orion Corporation
Timo Lappalainen Olli Huotari
President and CEO SVP, Corporate Functions
Contact person:
Olli Huotari, SVP, Corporate Functions, phone +358 50 966 3054
Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo
www.orion.fi
Orion is an innovative European R&D-based pharmaceutical and diagnostic company
with a special emphasis on developing medicinal treatments and diagnostic tests
for global markets. Orion develops, manufactures and markets human and
veterinary pharmaceuticals, active pharmaceutical ingredients and diagnostic
tests. Orion's pharmaceutical R&D focuses on the following core therapy areas:
central nervous system drugs, cancer and critical care drugs, and Easyhaler®
pulmonary drugs.
The Group's net sales in 2010 amounted to EUR 850 million. The Company invested
EUR 85 million in research and development. At the end of 2010, the Group had a
total of approximately 3,100 employees, of whom 2,450 worked in Finland and 650
in other countries. Orion's A and B shares are listed on NASDAQ OMX Helsinki.
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Orion Oyj via Thomson Reuters ONE
[HUG#1549825]
Unternehmensinformation / Kurzprofil:
Datum: 26.09.2011 - 12:26 Uhr
Sprache: Deutsch
News-ID 69526
Anzahl Zeichen: 3690
contact information:
Town:
Espoo
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 150 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Disclosure Under Chapter 2 Section 10"
steht unter der journalistisch-redaktionellen Verantwortung von
Orion Oyj (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
